Vertaling van "monthly reports " (Nederlands → Frans) :

These condensed consolidated financial statements for the three-month quarterly and the 12-month periods ended December 31, 2008, were prepared in accordance with International Accounting Standard 34 “Interim Financial Reporting” and accounting policies set out in the 2008 Annual Report published on January 28, 2009.
Les comptes consolidés simplifiés pour le trimestre et la période de douze mois se terminant le 31 décembre 2008 ont été établis conformément à la norme comptable internationale 34 concernant l’information financière intermédiaire (IAS 34 « Interim Financial Reporting ») et aux normes comptables décrites dans le rapport annuel 2008 publié le 28 janvier 2009.

Treatment (both NRT and bupropion) lasts at least 1 month Retail price of NRT gum: not reported Retail price of NRT patch (3-month course): €354.54 (€, 2001) Retail price of NRT nasal spray (3-months course): €743.02 3% (range 0-5% in sensitivity analysis)
Treatment (both NRT and Buproprion) lasts at least 1 month Retail price of NRT gum: not reported Retail price of NRT patch (3-month course): €354.54 (€, 2001) Retail price of NRT nasal spray (3-months course): €743.02 3% (range 0-5% in sensitivity analysis)

In addition to monthly reports containing financial information prepared under International Financial Reporting Standards (IFRS), senior management will receive a monthly analysis incorporating these core measures.
En plus des rapports mensuels contenant des informations financières préparées selon les normes IFRS (International Financial Reporting Standards), les cadres dirigeants recevront une analyse mensuelle intégrant ces mesures «core».

In addition to monthly reports containing financial information prepared under International Financial Reporting Standards (IFRS), senior management receives a monthly analysis incorporating these core measures.
En plus des rapports mensuels contenant des informations financières préparées selon les normes IFRS (International Financial Reporting Standards), les cadres dirigeants reçoivent une analyse mensuelle intégrant ces mesures core.

Odds ratio of NRT versus control: 1.67 Odds ratio of bupropion versus control: 2.1 Odds ratio of NRT+bupropion versus control: 2.65 From these Odds Ratios and information on the control 12-month quit rate in the comparator intervention (0.04 for brief advice and 0.10 for counselling), the 12-month quit rate of treatment is calculated: treated quit rate for brief advice+NRT: 0.0650 treated quit rate for brief advice+bupropion: 0.0805 treated quit rate for brief advice+bupropion+NRT: 0.0994 treated quit rate for counselling+NRT: 0.1565 treated quit rate for counselling+bupropion: 0.1892 treated quit rate for counselling+bupropion+NRT: 0.2275 spontaneous cessation rate: 0.01. lifetime relapse rate: 40% (range 30-50%). number of LYG per quitter: 2 (range 1-3). number of QALYs gained per quitter: 2.7 (range 1.35-4.05) not reported The table gives an overview of the assumptions with respect to costs and effects (quit rates) in the average scenario.
Odds ratio of NRT versus control: 1.67 Odds ratio of Buproprion versus control: 2.1 Odds ratio of NRT+Buproprion versus control: 2.65 From these Odds Ratios and information on the control 12-month quit rate in the comparator intervention (0.04 for brief advice and 0.10 for counselling), the 12-month quit rate of treatment is calculated: treated quit rate for brief advice+NRT: 0.0650 treated quit rate for brief advice+Buproprion: 0.0805 treated quit rate for brief advice+Buproprion+NRT: 0.0994 treated quit rate for counselling+NRT: 0.1565 treated quit rate for counselling+Buproprion: 0.1892 treated quit rate for counselling+Buproprion+NRT: 0.2275 spontaneous cessation rate: 0.01. lifetime relapse rate: 40% (range 30-50%). number of LYG per quitter: 2 (range 1-3). number of QALYs gained per quitter: 2.7 (range 1.35-4.05) not reported The table gives an overview of the assumptions with respect to costs and effects (quit rates) in the average scenario.

The following is a non-exhaustive list relating to some cases reported in the 2008 Annual Report and includes information as of the first nine months in 2009:
Non exhaustive, la liste suivante passe en revue quelques-uns des cas cités dans le Rapport annuel 2008 et contient les informations disponibles au cours des neuf premiers mois de 2009.

These Condensed Interim Consolidated Financial Statements for the three- and nine-month periods ended September 30, 2010, were prepared in accordance with International Accounting Standard 34 Interim Financial Reporting and accounting policies set out in the 2009 Annual Report published on January 26, 2010, except as indicated below.
Les comptes consolidés intermédiaires simplifiés pour les périodes de trois et neuf mois se terminant le 30 septembre 2010 ont été établis conformément à la norme comptable internationale IAS 34 Information financière intermédiaire et aux normes comptables décrites dans le rapport annuel 2009 publié le 26 janvier 2010, sauf indication contraire ci-dessous.

These Condensed Interim Consolidated Financial Statements for the three- and six-month periods ended June 30, 2010, were prepared in accordance with International Accounting Standard 34 Interim Financial Reporting and accounting policies set out in the 2009 Annual Report published on January 26, 2010, except as indicated below.
Les comptes consolidés intermédiaires simplifiés pour les périodes de trois et six mois se terminant le 30 juin 2010 ont été établis conformément à la norme comptable internationale IAS 34 Information financière intermédiaire et aux normes comptables décrites dans le rapport annuel 2009 publié le 26 janvier 2010, sauf indication contraire ci-dessous.

These Condensed Interim Consolidated Financial Statements for the three-month period ended March 31, 2010, were prepared in accordance with International Accounting Standard 34 Interim Financial Reporting and accounting policies set out in the 2009 Annual Report published on January 26, 2010, except as indicated below.
Les comptes consolidés intermédiaires simplifiés pour la période de trois mois se terminant le 31 mars 2010 ont été établis conformément à la norme comptable internationale IAS 34 Information financière intermédiaire et aux normes comptables décrites dans le rapport annuel 2009 publié le 26 janvier 2010, sauf indication contraire ci-dessous.

De odds-verhouding (schatting van het relatieve risico), gecorrigeerd voor leeftijd, bedroeg in de ene studie 2,7 (95 % betrouwbaarheidsinterval van 1,5 tot 4,7), in de andere studie 2,8 (95 % betrouwbaarheidsinterval van 2,1 tot 3,8). Naar aanleiding van deze nieuwe gegevens publiceerde het EMA een waarschuwing (via www.ema.europa.eu (zoekterm: drospirenone; kies: " PhVWP Monthly Report May 2011" ) en de SKP’s van de specialiteiten op basis van drospirenon (Yasmin®, Yasminelle® en Yaz®) werden in die zin aangepast.
Suite à ces nouvelles données, l’EMA a publié un avertissement (via www.ema.europa.eu (mots-clé: drospirenone; choisir : " PhVWP Monthly Report May 2011" ) et les RCP des spécialités à base de drospirénone (Yasmin®, Yasminelle® et Yaz®) ont été adaptés dans ce sens.